[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Gastroesophageal reflux disease (GERD) is a wide spread disease characterized by distinct clinical polymorphism manifesting with various symptoms and/or inflammatory changes of a distal portion of the esophagus. Current first-line therapy in GERD consists in administration of proton pump inhibitors (PPI) which promote faster relief of the symptoms and healing of erosive-ulcerous lesions of esophageal mucosa in GERD patients. Clinical efficacy of standard and novel PPI is compared. Wide use of PPI and their long-term courses require further study of PPI side effects which now lack attention from the clinical researchers.
Maev
I V
IV
Balashova
N N
NN
Busarova
G A
GA
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D013454:Sulfoxides / Q000627:therapeutic use; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D064747:Lansoprazole; D064750:Rabeprazole; D000077402:Pantoprazole; D009853:Omeprazole